Osteoclast inhibitors for knee conditions
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as knee pain.
Claims24
A method of treating osteoarthritis comprising orally administering zoledronic acid to a person suffering from osteoarthritis and having a bone marrow lesion, wherein the person has knee pain, and a pain intensity of 5 or greater measured using the 0-10 numerical rating scale (NRS) or 5 cm or greater using the 10 cm visual analog scale (VAS), and wherein about 200 mg to about 400 mg of the zoledronic acid is administered within 2 months.
Dependencies are inferred from the claim text.